[1] GUTMANN D H,FERNER R E,LISTERNICK R H,et al. Neurofibromatosis type 1[J]. Nat Rev Dis Primers,2017,3:17004.
[2] NIX J S,BLAKELEY J,RODRIGUEZ F J. An update on the central nervous system manifestations of neurofibromatosis type 1[J]. Acta Neuropathol,2020,139(4):625-641.
[3] WILSON B N,JOHN A M,HANDLER M Z,et al. Neurofibromatosis type 1:new developments in genetics and treatment[J]. J Am Acad Dermatol,2021,84(6):1667-1676.
[4] GROSS A M,WOLTERS P L,DOMBI E,et al. Selumetinib in children with inoperable plexiform neurofibromas[J]. N Engl J Med,2020,382(15):1430-1442.
[5] 中国Ⅰ型神经纤维瘤病多中心治疗协作组,全国整形外科多中心研究平台. Expert consensus on diagnosis and management of neurofibromatosis type 1(2021 edition)[J]. 中国修复重建外科杂志,2021,35(11):1384-1395.
[6] National Cancer Institute(NCI). Azd6244 hydrogen sulfate for children with nervous system tumors[J]. ClinicalTrialsgov,2011,https://clinicaltrials.gov/study/NCT01362803.
[7] KAISER A E,BANIASADI M,GIANSIRACUSA D,et al. Sulfo-raphane:a broccoli bioactive phytocompound with cancer preventive potential[J]. Cancers (Basel),2021,13(19):4796.
[8] ZHANG Z,GARZOTTO M,DAVIS E W,et al. Sulforaphane bioa-vailability and chemopreventive activity in men presenting for biopsy of the prostate gland:a randomized controlled trial[J]. Nutr Cancer,2020,72(1):74-87.
[9] XIE H,RUTZ J,MAXEINER S,et al. Plant-derived sulforaphane suppresses growth and proliferation of drug-sensitive and drug-resistant bladder cancer cell lines in vitro[J]. Cancers (Basel),2022, 14(19):4682.
[10] ZUO M,CHEN H,LIAO Y,et al. Sulforaphane and bladder cancer:a potential novel antitumor compound[J]. Front Pharmacol,2023, 14:1254236.
[11] SOMATILAKA B N,SADEK A,MCKAY R M,et al. Malignant peri-pheral nerve sheath tumor:models,biology,and translation[J]. Onco-gene,2022,41(17):2405-2421.
[12] BROSSEA J P,LIAO C P,WANG Y,et al. Nf1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation[J]. Nat Commun,2018,9(1):5014.
[13] GU H,MAO X,DU M. Metabolism,absorption,and anti-cancer effects of sulforaphane:an update[J]. Crit Rev Food Sci Nutr,2022, 62(13):3437-3452.
[14] SING K B,KIM S H,HAHM E R,et al. Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism[J]. Carcinogenesis,2018,39(6):826-837.
[15] PATEL A V,JOHANSSON G,COLBERT M C,et al. Fatty acid synthase is a metabolic oncogene targetable in malignant peripheral nerve sheath tumors[J]. Neuro Oncol,2015,17(12):1599-1608.
[16] SUPPIAH S,MANSOURI S,MAMATJAN Y,et al. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities[J]. Nat Commun,2023,14(1):2696.
[17] WATSON A L,RAHRMANN E P,MORIARITY B S,et al. Canonical wnt β-catenin signaling drives human schwann cell[J]. Cancer Discov,2013,3:674-689.
[18] PALOMO-IRIGOYEN M,P?魪REZ-ANDR?魪S E,IRUARRIZAGA-LEJARRETA M,et al. Hur/elavl1 drives malignant peripheral nerve sheath tumor growth and metastasis[J]. J Clin Invest,2020,130(7):3848-3864.
[19] BURNETT J P,LIM G,LI Y,et al. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells[J]. Cancer Lett,2017,394:52-64.
[20] BERNKOPF D B,DAUM G,BR?譈CKNER M,et al. Sulforaphane inhibits growth and blocks wnt/β-catenin signaling of colorectal cancer cells[J]. Oncotarget,2018,9:33892-33994.
[21] VERGARA DSE,GUERRA F,PRIORE P,et al. Beta-catenin kno-ckdown affects mitochondrial biogenesis and lipid metabolism in breast cancer cells[J]. Front Physiol,2017,8:544.
[22] YAO Y,SUN S,WANG J,et al. Canonical wnt signaling remodels lipid metabolism in zebrafish hepatocytes following ras oncogenic insult[J]. Cancer Res,2018,78(19):5548-5560.
[23] ZHENG S,LIN J ,PANG Z,et al. Aberrant cholesterol metabolism and wnt/beta-catenin signaling coalesce via frizzled5 in supporting cancer growth[J]. Adv Sci (Weinh),2022,9(28):e2200750.